Business News • PR NewsWire • Basal Insulin Peglispro Studies Demonstrate Superiority to Insulin Glargine Across Multiple Measures in People with Type 1 Diabetes

Basal Insulin Peglispro Studies Demonstrate Superiority to Insulin Glargine Across Multiple Measures in People with Type 1 Diabetes

Basal Insulin Peglispro Studies Demonstrate Superiority to Insulin Glargine Across Multiple Measures in People with Type 1 Diabetes

INDIANAPOLIS, June 6, 2015 /PRNewswire/ -- In newly released Phase III trial data, Eli Lilly and Company's (NYSE: LLY) basal insulin peglispro (BIL) demonstrated statistically significantly lower hemoglobin A1c (HbA1c) compared to insulin glargine at 26 and 52 weeks in people with...

View More : http://www.prnewswire.com/news-releases/basal-insulin-peglispro-studies-demonstrate-superiority-to-insulin-glargine-acro...

Releted News by prnewswire

Mohed Altrad of Altrad Group from France named EY World Entrepreneur Of The Year 2015

iTeknik Holding Corporation Seeks Acquisitions to Start New Expansion Program

Camali Clinic Launches Bounce Back Programme for Adolescents With Behavioural and Emotional Difficulties

Sono più di 7.000 i professionisti prevenienti da tutto il mondo che discuteranno risposte nuove a vecchi quesiti nel campo delle allergie e dell'immunologia